Rohto Pharmaceutical Co.,Ltd.
Rohto Pharmaceutical Co., Ltd. Q1 2027 Consolidated Financial Highlights
Announced Q1 2027 consolidated results and earnings guidance. Net sales of 91,624 million yen, operating income of 13,663 million yen, a marked YoY profit increase. Mentions contributions by segments and outlook revisions.
Key Figures
- Net sales: 91,624 million yen
- Operating income: 13,663 million yen
- EBITDA: 18,159 million yen
AI要約
Section heading
In the Q1 2027 period, the consolidated results show sales exceeding the previous year and a substantial rise in operating income. Contributions by region and by product are illustrated with charts, and revisions to the outlook are discussed.
Second section heading
From the perspective of shareholder returns and financial stability, the improved performance this period could enhance cash generation and serve as a foundation for long-term capital policy. The performance of core brands and contributions from overseas markets are emphasized as growth drivers going forward.
Net Sales Trend
Operating Income Trend
Segment Net Sales
Profit Margin Analysis
Forecast vs. Actual
Rohto Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
